TrialSpark debuts first clinical trial sites as part of deal with Novartis

Patients in a hospital waiting room
New York-based tech CRO TrialSpark launched its first clinical trial site as part of a partnership with Novartis that takes a new direction. (Getty/SuwanPhoto)

New York-based tech CRO TrialSpark launched its first clinical trial sites as part of a partnership with Novartis that takes a new direction.

TrialSpark’s approach addresses issues with trial participants who don’t live near large academic centers or hospital-based trial sites by allowing them to participate at their local doctor’s office. The new model is designed to accelerate clinical trials by expanding the pool of patient participants.

To support the new approach, the company built an end-to-end tech platform that includes precision-targeted recruitment, algorithmically prioritized queues, risk-based quality monitoring and cloud-based CTMS/eSource data capture.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

“If you don’t live near an academic center or an existing trial site, you often will need to travel far distances to access clinical trials and leave your doctor to participate,” Benjamine Liu, co-founder and chief executive of TrialSpark, said in a statement. “Our model changes this, enabling patients to participate in clinical trials at their local doctor’s office.”

By sifting through large data sets of deidentified health records, the company is able to find high-potential “hot spots” where likely trial participants can be found. Those patients/sites are usually overlooked due to their distance from large institutions and specialist centers.

Suggested Articles

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.

Charles River Labs has inked a licensing deal with drug discovery and development services provider Crown Bioscience for expanded access to the ZDSD rat model.